遗传检测市场Share, Size, Trends, Industry Analysis Report, By Disease Type (Hereditary Cancer Testing, Hereditary Non-Cancer Testing; By Technology (Cytogenetic, Biochemical, Molecular Testing); By Regions; Segment Forecast, 2020 - 2027

报告摘要

The global hereditary testing market was valued at USD 5.78 billion in 2019 and is expected to grow at a CAGR of 6.2% during the forecast period. A surge in the prevalence of hereditary diseases, awareness among the general population about the ill effects, innovations in genetic testing, and the emergence of rare diseases are the prime factors responsible for the market growth. Moreover, most of the players are focusing on women’s health inherited diseases and expanding their reach in the continuously evolving market space.

Furthermore, an increase in newborn screening increased the sales of genetic testing kits. In November 2019, the Virginia Department of General Services tested 7,868 infants for approximately 31 genetic and metabolic disorders. Thus, increased penetration of newborn screening further boosted the revenue for hereditary testing market.

了解有关此报告的更多信息：request for sample pages

Industry Dynamics

Growth Drivers
遗传测试程序的改革使得为世袭癌症添加了多基因面板。国家综合癌症网络（NCCN）卵巢，结直肠癌和乳腺癌的指导方针提供有关测试面板的癌症风险因素，管理和建议的信息。预计分销模式的最新发展将有利于遗传性疾病检测市场。

Technology providers play an important role in the industry by improving distribution services. Most of the companies are using cloud-based models to make bioinformatics expertise to all the stakeholders. For instance, as of March 2019, more than 14 licenses were issued for the Constellation software, used for non-invasive prenatal testing products and services. Although, hereditary genetic testing has huge advantages over traditional tests, still, experts believe test cost and data security concerns make worry consumers.

U.Seons患有遗传性遗传疾病的美国有超过三万人，患者经常被误诊，有时长期诊断时间表导致昂贵的医疗保健奥德赛。betway体育亚洲版入口RDI将以医疗权利要求，遗传密码，WES数据和电子健康记录的形式利用AI，ML和NLP算法，以便能够使制药公司能够在药物商业化，临床试验规划和药物开发中获取知情裁决和发现程序。因此，具有这种专用的遗传检测方法，遗传疾病的遗传检测，预计在即将到来的年份将富有成效。

遗传检测市场Report Scope

The market is primarily segmented on the basis of disease type, technology, and region.

通过疾病类型	通过技术	按地区
Hereditary Cancer Testing 肺癌 Breast Cancer 结直肠癌 Cervical Cancer 卵巢癌 Prostate Cancer Stomach/Gastric Cancer Melanoma 肉瘤 子宫癌 胰腺癌 Others Hereditary Non-cancer Testing 遗传测试 心脏病疾病 Rare Diseases 其他疾病 Newborn Genetic Screening 预体遗传诊断和筛选 非侵入性产前检测（NIPT）和载体筛查测试	Cytogenetic 生物化学 分子测试	北美（美国，加拿大） 欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） 亚太地区(日本、中国、印度、马来西亚、Indonesia. South Korea) 拉丁美洲（巴西，墨西哥，阿根廷） MEA（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

Insight by Disease Type

Based on the disease type, the market is categorized into hereditary cancer testing and hereditary non-cancer testing. In 2019, the hereditary cancer testing segment is expected to dominate the market. The decline in the cost of cancer testing and the rising prevalence of different forms of cancer are key segment drivers. For instance, Color Genomics cancer screening product priced at around USD 259, whereas, products of Myriad, were priced at USD 4,000.

遗传性癌症检测的低成本替代品使这些产品的负担能力使得一般人群，特别是患有乳腺癌，宫颈和肺癌的人们。BRCA1载体具有超过80％的风险诱导乳腺癌。由人乳头瘤病毒（HPV）引起的宫颈癌也推动了癌症检测产品和服务的摄取。必威开户注册

Geographic Overview

该市场分叉进入北美，欧洲，亚太地区，拉丁美洲和中东和非洲（MEA）。欧洲占2019年最大的收入份额，预计将在预测期内见证大幅增长。这可以归因于几个因素，如在该地区运营的关键球员，政府赞助的治疗，有利的政府政策，使遗传测试能够为一般人群负担得起。

预计北美将占2027年底截至2027年底的重大收入份额，该区域的增长归因于若干监管框架，高普遍性和对遗传性疾病的不良影响和经济负担的普及和意识，以及商业批准遗传测试。根据国家卫生大学研究所（NIH）的估计，美国超过3000万人患有大约7,000个遗传性疾病。随着在进行基因组测试的患者数量的增加，收入水平上升，必然会支持区域增长。

竞争洞察力

Key players operating in the global hereditary testing market include Myriad Genetics, Inc.; Natera, Inc.; F. Hoffmann-La Roche Ltd; Invitae Corporation; Illumina, Inc., Fulgent Genetic, Inc.; Quest Diagnostics Incorporated; Thermo Fisher Scientific, Inc.; Twist Bioscience; Agilent Technologies, Inc.; Sophia Genetics; Medgenome; and CENTOGENE N.V.